×
Pharma Mar Inventory 2019-2024 | PHMMF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pharma Mar inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
View More
Pharma Mar Inventory 2019-2024 | PHMMF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pharma Mar inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.9B
Regeneron Pharmaceuticals (REGN)
$125.5B
Vertex Pharmaceuticals (VRTX)
$122.4B
Gilead Sciences (GILD)
$104.4B
Bristol Myers Squibb (BMY)
$100.8B
CSL (CSLLY)
$96.8B
GSK (GSK)
$87.9B
Alnylam Pharmaceuticals (ALNY)
$35.1B
Argenex SE (ARGX)
$31.6B
Biogen (BIIB)
$28.8B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$26.9B
Illumina (ILMN)
$20.9B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.3B
BioMarin Pharmaceutical (BMRN)
$13.5B
Vaxcyte (PCVX)
$13B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.5B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.4B
Bio-Rad Laboratories (BIO.B)
$9.1B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.7B
Repligen (RGEN)
$8B
Halozyme Therapeutics (HALO)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B